5.73
price up icon1.96%   0.11
after-market Dopo l'orario di chiusura: 5.64 -0.09 -1.57%
loading
Precedente Chiudi:
$5.62
Aprire:
$5.41
Volume 24 ore:
1.46M
Relative Volume:
3.16
Capitalizzazione di mercato:
$192.71M
Reddito:
$2.81M
Utile/perdita netta:
$-97.34M
Rapporto P/E:
-3.6266
EPS:
-1.58
Flusso di cassa netto:
$-91.47M
1 W Prestazione:
+60.50%
1M Prestazione:
+128.29%
6M Prestazione:
+72.59%
1 anno Prestazione:
-26.06%
Intervallo 1D:
Value
$5.10
$5.74
Intervallo di 1 settimana:
Value
$3.54
$6.15
Portata 52W:
Value
$2.315
$10.13

Fulcrum Therapeutics Inc Stock (FULC) Company Profile

Name
Nome
Fulcrum Therapeutics Inc
Name
Telefono
617-651-8851
Name
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
Dipendente
45
Name
Cinguettio
@fulcrumtx
Name
Prossima data di guadagno
2024-11-05
Name
Ultimi documenti SEC
Name
FULC's Discussions on Twitter

Confronta FULC con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
FULC
Fulcrum Therapeutics Inc
5.73 192.71M 2.81M -97.34M -91.47M -1.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
500.19 127.64B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
603.58 65.95B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
656.65 37.92B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
273.55 32.98B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.16 26.89B 3.81B -644.79M -669.77M -6.24

Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-09-13 Downgrade H.C. Wainwright Buy → Neutral
2024-09-12 Downgrade BofA Securities Neutral → Underperform
2024-09-12 Downgrade Cantor Fitzgerald Overweight → Neutral
2024-09-12 Downgrade Leerink Partners Outperform → Market Perform
2024-09-12 Downgrade RBC Capital Mkts Outperform → Sector Perform
2024-09-12 Downgrade Stifel Buy → Hold
2024-09-09 Aggiornamento BofA Securities Underperform → Neutral
2024-05-20 Iniziato Cantor Fitzgerald Overweight
2024-03-13 Iniziato RBC Capital Mkts Outperform
2023-09-25 Iniziato Goldman Neutral
2023-08-23 Aggiornamento H.C. Wainwright Neutral → Buy
2023-08-22 Aggiornamento Stifel Hold → Buy
2023-05-04 Downgrade Goldman Buy → Neutral
2023-03-10 Downgrade Credit Suisse Outperform → Neutral
2023-03-10 Downgrade H.C. Wainwright Buy → Neutral
2023-03-09 Downgrade Stifel Buy → Hold
2023-02-28 Downgrade Morgan Stanley Overweight → Equal-Weight
2023-02-24 Downgrade BofA Securities Neutral → Underperform
2022-11-15 Iniziato Goldman Buy
2022-03-08 Iniziato Oppenheimer Outperform
2022-03-03 Aggiornamento BofA Securities Underperform → Neutral
2021-08-11 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2021-04-26 Ripresa Credit Suisse Outperform
2021-03-22 Iniziato Credit Suisse Outperform
2021-03-02 Iniziato Stifel Buy
2020-10-16 Iniziato Piper Sandler Overweight
2020-08-12 Downgrade BofA Securities Neutral → Underperform
2020-08-12 Reiterato H.C. Wainwright Buy
2020-08-12 Downgrade Morgan Stanley Overweight → Equal-Weight
2020-06-19 Downgrade BofA/Merrill Buy → Neutral
2020-06-17 Iniziato BTIG Research Buy
2019-10-03 Iniziato H.C. Wainwright Buy
2019-08-12 Iniziato BofA/Merrill Buy
Mostra tutto

Fulcrum Therapeutics Inc Borsa (FULC) Ultime notizie

pulisher
May 03, 2025

Fulcrum therapeutics targets key data from PIONEER trial in Q3 2025 - MSN

May 03, 2025
pulisher
May 02, 2025

Are Smart Investors Making the Right Decision? Fulcrum Therapeutics Inc (FULC) - Sete News

May 02, 2025
pulisher
May 02, 2025

Fulcrum Therapeutics Inc (FULC) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com

May 02, 2025
pulisher
May 02, 2025

Fulcrum Therapeutics Inc (FULC) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and ... - Yahoo Finance

May 02, 2025
pulisher
May 01, 2025

Fulcrum Therapeutics’ Positive Earnings Call Highlights - TipRanks

May 01, 2025
pulisher
May 01, 2025

Earnings call transcript: Fulcrum Therapeutics Q1 2025 reveals improved net loss By Investing.com - Investing.com South Africa

May 01, 2025
pulisher
May 01, 2025

Fulcrum Therapeutics Inc [FULC] stock for 1,831 USD was sold by Tourangeau Greg - knoxdaily.com

May 01, 2025
pulisher
May 01, 2025

Fulcrum Therapeutics Inc Q1 2025 Earnings: EPS of -$0.28 Beats E - GuruFocus

May 01, 2025
pulisher
May 01, 2025

FULC Achieves Milestone in Sickle Cell Disease Treatment Development | FULC Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

FULC Financial Update: Cash Position Shifts in Early 2025 | FULC Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Fulcrum Therapeutics (FULC) Target Price Adjusted Amid Strong Ca - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Are Fulcrum Therapeutics Inc’shares a good deal? - uspostnews.com

May 01, 2025
pulisher
May 01, 2025

Earnings call transcript: Fulcrum Therapeutics Q1 2025 reveals improved net loss - Investing.com

May 01, 2025
pulisher
May 01, 2025

Fulcrum Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat

May 01, 2025
pulisher
May 01, 2025

Fulcrum Therapeutics Inc. (FULC) Misses Q1 EPS by 2c - StreetInsider

May 01, 2025
pulisher
May 01, 2025

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025 - The Manila Times

May 01, 2025
pulisher
May 01, 2025

Fulcrum Therapeutics, Inc. SEC 10-Q Report - TradingView

May 01, 2025
pulisher
Apr 28, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 28, 2025
pulisher
Apr 26, 2025

Geode Capital Management LLC Sells 26,347 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

Apr 26, 2025
pulisher
Apr 25, 2025

Daily Progress: Fulcrum Therapeutics Inc (FULC) Drop -10.27, Closing at 3.32 - DWinneX

Apr 25, 2025
pulisher
Apr 24, 2025

Fulcrum Therapeutics Inc [NASDAQ: FULC] Sees Decrease in Stock Value - knoxdaily.com

Apr 24, 2025
pulisher
Apr 24, 2025

Fulcrum Therapeutics to Release First Quarter 2025 Financial Results on May 1, 2025 - Nasdaq

Apr 24, 2025
pulisher
Apr 24, 2025

Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET - The Manila Times

Apr 24, 2025
pulisher
Apr 24, 2025

Earnings Call Alert: Rare Disease Developer Fulcrum Therapeutics Sets Q1 2025 Results Date - Stock Titan

Apr 24, 2025
pulisher
Apr 23, 2025

Investing in Fulcrum Therapeutics Inc (FULC) might be a great opportunity, but the stock is a bit overvalued - uspostnews.com

Apr 23, 2025
pulisher
Apr 22, 2025

Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) PT at $8.63 - Defense World

Apr 22, 2025
pulisher
Apr 14, 2025

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Wellington Management Group LLP - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

American Century Companies Inc. Increases Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FULC Stock News - GuruFocus

Apr 12, 2025
pulisher
Apr 11, 2025

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 11, 2025
pulisher
Apr 08, 2025

We're Interested To See How Fulcrum Therapeutics (NASDAQ:FULC) Uses Its Cash Hoard To Grow - Yahoo Finance

Apr 08, 2025
pulisher
Apr 08, 2025

Fulcrum Therapeutics, Inc. (FULC) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire

Apr 08, 2025
pulisher
Apr 07, 2025

Fulcrum Therapeutics, Inc. Being Investigated on Behalf of Fulcrum Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire

Apr 07, 2025
pulisher
Apr 04, 2025

Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Business And Shares Still Trailing The Industry - simplywall.st

Apr 04, 2025
pulisher
Apr 01, 2025

Fulcrum Therapeutics stock hits 52-week low at $2.77 - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Fulcrum Therapeutics stock hits 52-week low at $2.77 By Investing.com - Investing.com UK

Apr 01, 2025
pulisher
Mar 29, 2025

Charles Schwab Investment Management Inc. Lowers Stock Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

Fulcrum Sheds Investor Suit Over Blood Treatment Trial Safety - Bloomberg Law News

Mar 28, 2025
pulisher
Mar 28, 2025

Brokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $8.63 - Defense World

Mar 28, 2025
pulisher
Mar 16, 2025

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FULC - Business Wire

Mar 16, 2025
pulisher
Mar 11, 2025

Fulcrum Therapeutics stock hits 52-week low at $2.85 By Investing.com - Investing.com Australia

Mar 11, 2025
pulisher
Mar 11, 2025

Fulcrum Therapeutics stock hits 52-week low at $2.85 - Investing.com India

Mar 11, 2025
pulisher
Mar 11, 2025

Fulcrum Therapeutics at Leerink’s Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com UK

Mar 11, 2025

Fulcrum Therapeutics Inc Azioni (FULC) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$72.58
price up icon 0.39%
$21.55
price up icon 0.33%
$33.00
price up icon 0.33%
$28.02
price up icon 0.43%
$101.10
price down icon 3.66%
biotechnology ONC
$254.16
price down icon 0.63%
Capitalizzazione:     |  Volume (24 ore):